-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Uric acid is the end product of purine metabolism in humans and other apes, and is the main antioxidant substance in plasma
Recently, researchers investigated the effect of inosine treatment, a precursor of urate, on the progression of early PD
This study is a randomized, double-blind, placebo-controlled, phase III trial to investigate the efficacy of oral inosine in the treatment of early Parkinson’s disease.
Because the effect of the interim analysis was not significant, the study ended early
The average MDS-UPDRS score of the inosine group increased by 11.
Differences in uric acid concentration, Parkinson's clinical progress, dopamine treatment needs, and dopamine transporter ligand binding ability between groups
Differences in uric acid concentration, Parkinson's clinical progress, dopamine treatment needs, and dopamine transporter ligand binding ability between groupsIn patients with early Parkinson's disease, compared with placebo, inosine treatment has no significant effect in delaying clinical disease progression.
In patients with early Parkinson’s disease, compared with placebo, inosine treatment has no significant effect in delaying clinical disease progression.
Original source:
The Parkinson Study Group SURE-PD3 Investigators.
Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression The SURE-PD3 Randomized Clinical Trial.
JAMA
Leave a message here
